High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing
Высокопроизводительная проточная микрофлюидная электропорация мРНК в первичные человеческие T-клетки для применения в производстве клеточной терапии
2020-10-22
SCID: 54.1/f6jvyw4b
Discuss with AI
CRISPR/Cas9 gene editingcellular therapy manufacturingcontinuous-flow microfluidic electroporationmRNA deliveryprimary human T cells
Figures from the paper
Abstract (AI)
Implementation of gene editing technologies such as CRISPR/Cas9 in the manufacture of novel cell-based therapeutics has the potential to enable highly-targeted, stable, and persistent genome modifications without the use of viral vectors. Electroporation has emerged as a preferred method for delivering gene-editing machinery to target cells, but a major challenge remaining is that most commercial electroporation machines are built for research and process development rather than for large-scale, automated cellular therapy manufacturing. Here we present a microfluidic continuous-flow electrotransfection device designed for precise, consistent, and high-throughput genetic modification of target cells in cellular therapy manufacturing applications. We optimized our device for delivery of mRNA into primary human T cells and demonstrated up to 95% transfection efficiency with minimum impact on cell viability and expansion potential. We additionally demonstrated processing of samples comprising up to 500 million T cells at a rate of 20 million cells/min. We anticipate that our device will help to streamline the production of autologous therapies requiring on the order of 10[Formula: see text]-10[Formula: see text] cells, and that it is well-suited to scale for production of trillions of cells to support emerging allogeneic therapies.
Key Findings
1
A continuous-flow microfluidic electrotransfection device was developed for precise, consistent, high-throughput genetic modification in cellular therapy manufacturing.
2
The device achieved up to 95% mRNA transfection efficiency in primary human T cells while minimally affecting viability and expansion potential.
3
The platform is intended to streamline autologous therapy manufacturing and offers scalability toward trillions of cells for emerging allogeneic therapies.
4
The system processed samples containing up to 500 million T cells at a rate of 20 million cells per minute.
Research Object
primary human T cells undergoing continuous-flow microfluidic electroporation for mRNA delivery
Research Subject
high-throughput mRNA electrotransfection performance, including transfection efficiency, cell viability, expansion potential, and scalable processing capacity
Publication Details
Publication Date
2020-10-22
Journal
Publisher
ISSN
Cited by
87
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest